Tags

Type your tag names separated by a space and hit enter

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
Mov Disord. 2006 Dec; 21(12):2078-81.MD

Abstract

Psychosis affects at least 5% to 8% of medication-treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD-related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double-blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open-label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open-label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising.

Authors+Show Affiliations

Parkinson Disease and Movement Disorders Center, NeuroHealth, Warwick, Rhode Island 02886, USA. joseph_friedman@brown.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17013906

Citation

Friedman, Joseph H., et al. "Open-label Flexible-dose Pilot Study to Evaluate the Safety and Tolerability of Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 21, no. 12, 2006, pp. 2078-81.
Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006;21(12):2078-81.
Friedman, J. H., Berman, R. M., Goetz, C. G., Factor, S. A., Ondo, W. G., Wojcieszek, J., Carson, W. H., & Marcus, R. N. (2006). Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 21(12), 2078-81.
Friedman JH, et al. Open-label Flexible-dose Pilot Study to Evaluate the Safety and Tolerability of Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease. Mov Disord. 2006;21(12):2078-81. PubMed PMID: 17013906.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. AU - Friedman,Joseph H, AU - Berman,Robert M, AU - Goetz,Christopher G, AU - Factor,Stewart A, AU - Ondo,William G, AU - Wojcieszek,Joanne, AU - Carson,William H, AU - Marcus,Ronald N, PY - 2006/10/3/pubmed PY - 2007/2/21/medline PY - 2006/10/3/entrez SP - 2078 EP - 81 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 21 IS - 12 N2 - Psychosis affects at least 5% to 8% of medication-treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD-related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstrated to be efficacious and tolerated in double-blind controlled trials. This study evaluated the effect of aripiprazole, an atypical antipsychotic, on psychosis in PD in an open-label pilot study. Fourteen patients meeting entry criteria were started on aripiprazole 1 mg/day and titrated up to a maximum dose of 5 mg as needed. Subjects were evaluated on the Unified Parkinson's Disease Rating Scale (UPDRS) part III for motor function, the Neuropsychiatric Inventory (NPI), and the Brief Psychiatric Rating Scale (BPRS) for psychiatric response. Statistically significant improvement in mean BPRS and positive BPRS subscales occurred with open-label aripiprazole, but eight subjects discontinued the study due to worsened Parkinsonism (three), worsened psychosis (two), worsening of both (two), and lack of efficacy (one). While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/17013906/Open_label_flexible_dose_pilot_study_to_evaluate_the_safety_and_tolerability_of_aripiprazole_in_patients_with_psychosis_associated_with_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.21091 DB - PRIME DP - Unbound Medicine ER -